By promoting healthy cardiac remodeling, Ang2 treatment may help rescue some of the cardiac abnormalities seen in HGPS patients, such as LV hypertrophy and systolic dysfunction. This evidence concerns the gene ANGPT2 and Hutchinson-Gilford progeria syndrome.